A new melanoma vaccine which has almost halved the rate of recurrence is being hailed as cancer’s “penicillin moment”.

In an early stage clinical trial including 79 Australian patients, the personalised vaccine, made by Moderna, produced a 44 per cent reduction in the rate at which skin cancer returned.

Co-Medical Director at the Melanoma Institute Professor Georgina Long said on 6PR Mornings "it's the first study in the world to demonstrate the personalisation of a vaccine and using mRNA technology together."

"It seems to have a very strong signal of improving outcomes for patients," she told Gary. 

A new melanoma vaccine which has almost halved the rate of recurrence is being hailed as cancer’s “penicillin moment”.
In an early stage clinical trial including 79 Australian patients, the personalised vaccine, made by Moderna, produced a 44 per cent reduction in the rate at which skin cancer returned.
Co-Medical Director at the Melanoma Institute Professor Georgina Long said on 6PR Mornings "it's the first study in the world to demonstrate the personalisation of a vaccine and using mRNA technology together."
"It seems to have a very strong signal of improving outcomes for patients," she told Gary.

Perth Today will keep you up to date with all the latest breaking stories and issues in Perth.

Perth Today will keep you up to date with all the latest breaking stories and issues in Perth.

Advertisement